Results 131 to 140 of about 7,553 (206)

Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Hetta HF, Salama A, Aljuaid TA, Mojmami YT, Alotibi RS, Alqabaly AM, Aldosari NA, Alshahri SA, Asiri WIA, Alamri RS, Alanazi FA, Alenazi MSA, Albuhayri MH, Ramadan YN, Sayad R.   +14 more
europepmc   +1 more source

Design and application of a fluorescent probe for imaging of endogenous Bruton's tyrosine kinase with preserved enzymatic activity. [PDF]

RSC Chem Biol
Valaka AP, Nyström H, Håversen L, Benitez-Martin C, Schäfer C, Jang WS, Camponeschi A, Andréasson J, Borén J, Grøtli M.   +9 more
europepmc   +1 more source

Bruton's tyrosine kinase (Btk) と結合する新規分子の同定とその解析 [PDF]

マツシタ, マサト, 松下, 正人
core  

Modulating the Binding Kinetics of Bruton's Tyrosine Kinase Inhibitors through Transition-State Effects. [PDF]

J Am Chem Soc
Bravo E, Li Y, Lin DY, Srinivasan B, Barone M, Li SX, DelloRusso F, Rahiyanath AS, Corrionero A, Alfonso P, Prendiville N, Kozakov D, Andreotti AH, Tonge PJ.   +13 more
europepmc   +1 more source

In Silico Molecular Docking Analysis of Valproic Acid as an Inhibitor of Bruton's Tyrosine Kinase: Potential Drug Repurposing for Allergies. [PDF]

Cureus
Martinez-Martinez RE, Calva-Hernandez CI, Rodriguez-Lopez GM, Soria-Castro R, Ruiz-Sanchez BP, Chavez-Blanco AD, Pérez-Tapia SM, Pavano-Rodriguez CG, Chacon-Salinas R.   +8 more
europepmc   +1 more source

Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Clin Hematol Int
Vatvani AD, Hariyanto TI, Ramirez AC, Shabarek N.   +3 more
europepmc   +1 more source

The new Bruton's tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres. [PDF]

Transl Oncol
Jo E, Lee E, Oh Y, Lee D, Lee B, Kim K, Choi RJ, Hong J, Jeon Y, Cho H, Choi YS, Kim S, Won SY, Choi S, Roh TH, Moon JH, Kim EH, Chang JH, Jeon R, Kang SG.   +19 more
europepmc   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

Bruton's Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View. [PDF]

Mediterr J Hematol Infect Dis
Molica S, Allsup D.
europepmc   +1 more source

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience. [PDF]

Hemasphere
Innocenti I, Mosca A, Tomasso A, Galitzia A, Scarfò L, Morelli F, Galli E, Martini F, Sangiorgi E, Laureana R, Benintende G, Mattiello V, Chiriu S, Del Principe MI, Zamprogna G, Gentile M, Martino EA, Cappello E, Montalbano MC, Farina G, Innao V, Stirparo L, Patti C, Sportoletti P, Fresa A, Catania G, Coscia M, Bellesi S, Tedeschi A, Sanna A, Visentin A, Autore F, Pasquale R, Trentin L, Varettoni M, Ghia P, Murru R, Laurenti L.   +37 more
europepmc   +1 more source